ANAB vs CRL · rev $234.6M vs rev $2.00B
AnaptysBio Inc (ANAB) versus Charles River Laboratories (CRL) — a side-by-side from cached financials, not a winner call.
AnaptysBio Inc (ANAB) is a biotechnology company listed on NASDAQ.
Charles River Laboratories (CRL) is a diagnostics & research company listed on US.
Latest reported ANAB revenue for 2025-12-31 was $234.6M. Net income was -$13.2M. Revenue was up 157.0% from 2024-12-31 to 2025-12-31. ANAB currently screens at market cap $1.62B.
Latest reported CRL revenue for 2026-06-27 was $2.00B. Net income was -$16.3M. CRL currently screens at market cap $7.78B.
ANAB currently screens at market cap $1.62B. CRL currently screens at market cap $7.78B.
Not investment advice. Open the ANAB and CRL stock pages for the full models.
Not investment advice.